Efficacy of 0.28 % Sodium hyaluronate eyedrop in patient with evaporative dry eye in Rajavithi Hospital: randomized double-blind controlled trial.

Phase 4

• Conditions: Dry eye disease; Efficacy; Artificial tears; 0.28% sodium hyaluronate eye drops

• Registration Number: TCTR20210219002
• Lead Sponsor: ational innovation agency, Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-19
• Study Completion: 2021-11-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age more than 18 years.
Ocular surface disease Index not more than 13
Noninvasive tear break up time less than 10 seconds, both eyes.
Schirmer 1 test more than 5.5 mm. (in 5 minutes), both eyes.

Exclusion Criteria

Oxford grading scale not more than 4
Previous preservative eye drop use in 1 week.
Previous ocular surgery in 4 months.
History of nasolacrimal duct obstruction.
Allergy to sodium hyaluronate.
History of other ocular disease for example glaucoma, uveitis.
History of contact lenses used.
History of use connective tissue disease for example rheumatoid arthritis SLE, Sjogren disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dry eyes indicating 2 time observation after medicinal delivered and 1 mount after Tear osmolarity,Dry eyes indicating 2 time observation after medicinal delivered and 1 mount after The non-invasive tear film break-up time,Dry eyes indicating 2 time observation after medicinal delivered and 1 mount after Oxford grading scale,Dry eyes indicating 2 time observation after medicinal delivered and 1 mount after Ocular Surface Disease Index score

Secondary Outcome Measures

Name	Time	Method
Side effect Interview after 1 mount medicinal delivered Patient interview